AZ Gains Japan Option To KHK Respiratory Antibody
This article was originally published in PharmAsia News
AstraZeneca is looking at extending its alliance with Japan's Kyowa Hakko Kirin for a respiratory disease antibody, picking up an option to commercialize the interleukin-targeting therapy in Japan in a move that will extend the UK-based firm’s respiratory interests in this major market.
You may also be interested in...
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.